The burgeoning landscape of therapy for excess body fat and type 2 metabolic disorder is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant distinctions in their pharmacological profiles and clinical trial results are emerging. Re… Read More

Showing promise in the arena of weight management management, retatrutide presents a distinct approach. Different from many existing medications, retatrutide functions as a double agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. This simultaneous stimulation pr… Read More